File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis

TitlePredicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis
Authors
Issue Date2016
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S602, abstract no. FRI-144 How to Cite?
AbstractBACKGROUND AND AIMS: Functional cure in chronic hepatitis B requires HBV DNA negativity, HBsAg loss and anti-HBs seroconversion. ARC-520 RNAi drug therapy targets cccDNA derived mRNA, including the full-length HBsAg transcript. Using a 19plex anti-HBs panel to map HBsAg epitopes, we have developed a predictive algorithm of an HBsAg clearance profile in patients undergoing HBsAg loss during tenofovir therapy, defined as reduced recognition at loop 1 and loop 2 HBsAg “a” determinant epitopes. Complimentary to this, we have developed assays to detect co-existing complexed anti-HBs (with HBsAg), and analysed the ARC- 520 cohorts with the aim of evaluating the impact of RNAi therapy on HBsAg loss, the identification of an HBsAg clearance profile and the development of co-existing anti-HBs …
DescriptionPoster Presentations - Predicting HBsAg clearance responses during ARC-520 RNA interference: no. FRI-144
Persistent Identifierhttp://hdl.handle.net/10722/234186
ISSN
2015 Impact Factor: 10.59
2015 SCImago Journal Rankings: 4.570

 

DC FieldValueLanguage
dc.contributor.authorWalsh, R-
dc.contributor.authorYuen, L-
dc.contributor.authorHammond, R-
dc.contributor.authorDeerain, J-
dc.contributor.authorGiven, B-
dc.contributor.authorSchluep, T-
dc.contributor.authorYuen, MF-
dc.contributor.authorChan, HLY-
dc.contributor.authorLai, CL-
dc.contributor.authorHamilton, J-
dc.contributor.authorLau, JY-
dc.contributor.authorFerrari, C-
dc.contributor.authorGish, RG-
dc.contributor.authorLocarnini, SA-
dc.date.accessioned2016-10-14T06:59:41Z-
dc.date.available2016-10-14T06:59:41Z-
dc.date.issued2016-
dc.identifier.citationThe International Liver Congress™ 2016 - The 51st Annual Meeting of the European Association for the Study of the Liver (EASL 2016), Barcelona, Spain, 13-17 April, 2016. In Journal of Hepatology, 2016, v. 64 n. 2 suppl., p. S602, abstract no. FRI-144-
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/234186-
dc.descriptionPoster Presentations - Predicting HBsAg clearance responses during ARC-520 RNA interference: no. FRI-144-
dc.description.abstractBACKGROUND AND AIMS: Functional cure in chronic hepatitis B requires HBV DNA negativity, HBsAg loss and anti-HBs seroconversion. ARC-520 RNAi drug therapy targets cccDNA derived mRNA, including the full-length HBsAg transcript. Using a 19plex anti-HBs panel to map HBsAg epitopes, we have developed a predictive algorithm of an HBsAg clearance profile in patients undergoing HBsAg loss during tenofovir therapy, defined as reduced recognition at loop 1 and loop 2 HBsAg “a” determinant epitopes. Complimentary to this, we have developed assays to detect co-existing complexed anti-HBs (with HBsAg), and analysed the ARC- 520 cohorts with the aim of evaluating the impact of RNAi therapy on HBsAg loss, the identification of an HBsAg clearance profile and the development of co-existing anti-HBs …-
dc.languageeng-
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatology-
dc.rights© 2016. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/-
dc.titlePredicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis-
dc.typeConference_Paper-
dc.identifier.emailYuen, MF: mfyuen@hku.hk-
dc.identifier.emailLai, CL: hrmelcl@hkucc.hku.hk-
dc.identifier.authorityYuen, MF=rp00479-
dc.identifier.authorityLai, CL=rp00314-
dc.identifier.doi10.1016/S0168-8278(16)01112-0-
dc.identifier.hkuros267700-
dc.identifier.volume64-
dc.identifier.issue2 suppl.-
dc.identifier.spageS602, abstract no. FRI-144-
dc.identifier.epageS602, abstract no. FRI-144-
dc.publisher.placeThe Netherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats